Therapeutic implications of targeting AKT signaling in melanoma

Enzyme Research

Volumn 2011, Issue 1, 2011, Pages

  Madhunapantula, Subbarao V ^a,b   Robertson, Gavin P ^a,b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b PENN STATE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 [2 (4 AMINO 1,2,5 OXADIAZOL 3 YL) 1 ETHYL 7 (3 PIPERIDINYLMETHOXY) 1H IMIDAZO[4,5 C]PYRIDIN 4 YL] 2 METHYL 3 BUTYN 2 OL; B RAF KINASE; BI 69A 11; CELL PROTEIN; CERAMIDE; ISOPROTEIN; ISOSELENOCYANATE 4; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MICRORNA 200; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; NVP BBD 130; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE B GAMMA; PROTEIN KINASE B INHIBITOR; PROTEIN PRAS40; PROTEIN SERINE THREONINE KINASE; SELENIUM DERIVATIVE; SMALL INTERFERING RNA; SORAFENIB; SR 13668; TOZASERTIB; TRICIRIBINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AKT3 GENE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CARCINOGENESIS; CELL SURVIVAL; CELLULAR DISTRIBUTION; DRUG POTENTIATION; DRUG SAFETY; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; EPIGENETICS; GENE; GENE MUTATION; HUMAN; INTRACELLULAR SIGNALING; LYMPH NODE METASTASIS; MELANOMA; METASTASIS POTENTIAL; NONHUMAN; PI3K GENE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; PTEN GENE; REVIEW;

EID: 84865849911     PISSN: 20900406     EISSN: 20900414     Source Type: Journal    
DOI: 10.4061/2011/327923     Document Type: Review

References (198)

1. Bunney T. D., Katan M., Phosphoinositide signalling in cancer: beyond PI3K and PTEN. Nature Reviews Cancer 2010 10 5 342 352 2-s2.0-77951568703 10.1038/nrc2842
2. Carnero A., The PKB/AKT pathway in cancer. Current Pharmaceutical Design 2010 16 1 34 44 2-s2.0-77949452524 10.2174/138161210789941865
3. Lazo J. S., Wipf P., Phosphatases as targets for cancer treatment. Current Opinion in Investigational Drugs 2009 10 12 1297 1304 2-s2.0-71249131319
4. Madhunapantula S. V., Robertson G. P., Is B-Raf a good therapeutic target for melanoma and other malignancies? Cancer Research 2008 68 1 5 8 2-s2.0-39149133664 10.1158/0008-5472.CAN-07-2038 (Pubitemid 351380097)
5. Madhunapantula S. V., Robertson G. P., The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma. Pigment Cell and Melanoma Research 2009 22 4 400 419 2-s2.0-67749086812 10.1111/j.1755-148X.2009.00585.x
6. Robertson G. P., Functional and therapeutic significance of Akt deregulation in malignant melanoma. Cancer and Metastasis Reviews 2005 24 2 273 285 2-s2.0-21544483506 10.1007/s10555-005-1577-9 (Pubitemid 40922799)
7. Inamdar G. S., Madhunapantula S. V., Robertson G. P., Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. Biochemical Pharmacology 2010 80 5 624 637 2-s2.0-77954216113 10.1016/j.bcp.2010.04.029
8. Stahl J. M., Cheung M., Sharma A., Trivedi N. R., Shanmugam S., Robertson G. P., Loss of PTEN promotes tumor development in malignant melanoma. Cancer Research 2003 63 11 2881 2890 2-s2.0-0038243115 (Pubitemid 36667160)
9. Stahl J. M., Sharma A., Cheung M., Zimmerman M., Cheng J. Q., Bosenberg M. W., Kester M., Sandirasegarane L., Robertson G. P., Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Research 2004 64 19 7002 7010 2-s2.0-4944249733 10.1158/0008-5472.CAN-04-1399 (Pubitemid 39331010)
10. Manning B. D., Cantley L. C., AKT/PKB signaling: navigating downstream. Cell 2007 129 7 1261 1274 2-s2.0-34250788809 10.1016/j.cell.2007.06.009 (Pubitemid 46962095)
11. Smalley K. S. M., Herlyn M., Targeting intracellular signaling pathways as a novel strategy in melanoma therapeutics. Annals of the New York Academy of Sciences 2005 1059 16 25 2-s2.0-32244442800 10.1196/annals.1339.005 (Pubitemid 43211606)
12. Hsu M. Y., Meier F., Herlyn M., Melanoma development and progression: a conspiracy between tumor and host. Differentiation 2002 70 9-10 522 536 2-s2.0-0036993573 10.1046/j.1432-0436.2002.700906.x (Pubitemid 36194317)
13. Chudnovsky Y., Khavari P. A., Adams A. E., Melanoma genetics and the development of rational therapeutics. Journal of Clinical Investigation 2005 115 4 813 824 2-s2.0-16844385347 10.1172/JCI200524808 (Pubitemid 40489381)
14. Wu H., Goel V., Haluska F. G., PTEN signaling pathways in melanoma. Oncogene 2003 22 20 3113 3122 2-s2.0-0038456399 10.1038/sj.onc.1206451 (Pubitemid 36713763)
15. Robertson G. P., Furnari F. B., Miele M. E., Glendening M. J., Welch D. R., Fountain J. W., Lugo T. G., Huang H. J. S., Cavenee W. K., In vitro loss of heterozygosity targets the PTEN/MMAC1 gene in melanoma. Proceedings of the National Academy of Sciences of the United States of America 1998 95 16 9418 9423 2-s2.0-0032483009 10.1073/pnas.95.16.9418 (Pubitemid 28506246)
16. Lee J. O., Yang H., Georgescu M. M., Cristofano A. D., Maehama T., Shi Y., Dixon J. E., Pandolfi P., Pavletich N. P., Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell 1999 99 3 323 334 2-s2.0-0033615538 10.1016/S0092-8674(00)81663-3 (Pubitemid 29519911)
17. Maehama T., Dixon J. E., PTEN: a tumour suppressor that functions as a phospholipid phosphatase. Trends in Cell Biology 1999 9 4 125 128 2-s2.0-0032904432 10.1016/S0962-8924(99)01519-6 (Pubitemid 29161437)
18. Waite K. A., Eng C., Protean PTEN: form and function. American Journal of Human Genetics 2002 70 4 829 844 2-s2.0-0036206130 10.1086/340026 (Pubitemid 34259300)
19. Gericke A., Munson M., Ross A. H., Regulation of the PTEN phosphatase. Gene 2006 374 1-2 1 9 2-s2.0-33646705667 10.1016/j.gene.2006.02.024 (Pubitemid 43737118)
20. Mikhail M., Velazquez E., Shapiro R., Berman R., Pavlick A., Sorhaindo L., Spira J., Mir C., Panageas K. S., Polsky D., Osman I., PTEN expression in melanoma: relationship with patient survival, Bcl-2 expression, and proliferation. Clinical Cancer Research 2005 11 14 5153 5157 2-s2.0-22344435644 10.1158/1078-0432.CCR-05-0397 (Pubitemid 41003700)
21. Madhunapantula S. V., Sharma A., Robertson G. P., PRAS40 deregulates apoptosis in malignant melanoma. Cancer Research 2007 67 8 3626 3636 2-s2.0-34248545489 10.1158/0008-5472.CAN-06-4234 (Pubitemid 46762147)
22. Stewart A. L., Mhashilkar A. M., Yang X. H., Ekmekcioglu S., Saito Y., Sieger K., Schrock R., Onishi E., Swanson X., Mumm J. B., Zumstein L., Watson G. J., Snary D., Roth J. A., Grimm E. A., Ramesh R., Chada S., PI3K blockade by Ad-PTEN inhibits invasion and induces apoptosis in radial growth phase and metastatic melanoma cells. Molecular Medicine 2002 8 8 451 461 2-s2.0-0036690393 (Pubitemid 36337489)
23. Stahl J. M., Sharma A., Cheung M., Zimmerman M., Cheng J. Q., Bosenberg M. W., Kester M., Sandirasegarane L., Robertson G. P., Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Research 2004 64 19 7002 7010 2-s2.0-4944249733 10.1158/0008-5472.CAN-04-1399 (Pubitemid 39331010)
24. Dankort D., Curley D. P., Cartlidge R. A., Nelson B., Karnezis A. N., Damsky W. E., You M. J., DePinho R. A., McMahon M., Bosenberg M., BrafV cooperates with Pten loss to induce metastatic melanoma. Nature Genetics 2009 41 5 544 552 2-s2.0-65649147543 10.1038/ng.356
25. Nogueira C., Kim K.-H., Sung H., Paraiso K. H.T., Dannenberg J.-H., Bosenberg M., Chin L., LyndaChin@dfci.harvard.edu Kim M., Minjung.Kim@moffitt. org Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis. Oncogene 2010 29 47 6222 6232 10.1038/onc.2010.349
26. Mounir Z., Krishnamoorthy J. L., Robertson G. P., Scheuner D., Kaufman R. J., Georgescu M. M., Koromilas A. E., Tumor suppression by PTENR equires the activation of the PKR-eIF2 α phosphorylation pathway. Science Signaling 2009 2 102 ra85 2-s2.0-77952492303 10.1126/scisignal.2000389
27. Cantley L. C., Neel B. G., New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proceedings of the National Academy of Sciences of the United States of America 1999 96 8 4240 4245 2-s2.0-0033551070 10.1073/pnas.96.8.4240 (Pubitemid 29190320)
28. Li LI., Ross A. H., Why is PTEN an important tumor suppressor? Journal of Cellular Biochemistry 2007 102 6 1368 1374 2-s2.0-36849018402 10.1002/jcb.21593 (Pubitemid 350223940)
29. Ramaswamy S., Nakamura N., Vazquez F., Batt D. B., Perera S., Roberts T. M., Sellers W. R., Regulation of G progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/akt pathway. Proceedings of the National Academy of Sciences of the United States of America 1999 96 5 2110 2115 2-s2.0-0033514509 10.1073/pnas.96.5.2110 (Pubitemid 29117876)
30. Huang W., Chang H. Y., Fei T., Wu H., Chen Y. G., GSK3 β mediates suppression of cyclin D2 expression by tumor suppressor PTEN. Oncogene 2007 26 17 2471 2482 2-s2.0-34247171828 10.1038/sj.onc.1210033 (Pubitemid 46597263)
31. Mirmohammadsadegh A., Marini A., Nambiar S., Hassan M., Tannapfel A., Ruzicka T., Hengge U. R., Epigenetic silencing of the PTEN gene in melanoma. Cancer Research 2006 66 13 6546 6552 2-s2.0-33746114249 10.1158/0008-5472.CAN- 06-0384 (Pubitemid 44085609)
32. Lopez-Bergami P., Fitchman B., Ronai Z., Understanding signaling cascades in melanoma. Photochemistry and Photobiology 2008 84 2 289 306 2-s2.0-41149170819 10.1111/j.1751-1097.2007.00254.x (Pubitemid 351424029)
33. Tamguney T., Stokoe D., New insights into PTEN. Journal of Cell Science 2007 120 23 4071 4079 2-s2.0-38349030742 10.1242/jcs.015230
34. Miller S. J., Lou D. Y., Seldin D. C., Lane W. S., Neel B. G., Direct identification of PTEN phosphorylation sites. FEBS Letters 2002 528 1-3 145 153 2-s2.0-0037174166 10.1016/S0014-5793(02)03274-X (Pubitemid 35258015)
35. Ueda Y., Su Y., Richmond A., CCAAT displacement protein regulates nuclear factor-kappa beta-mediated chemokine transcription in melanoma cells. Melanoma Research 2007 17 2 91 103 2-s2.0-34247601522 10.1097/CMR.0b013e3280a60888 (Pubitemid 46673902)
36. Dahia P. L. M., PTEN, a unique tumor suppressor gene. Endocrine-Related Cancer 2000 7 2 115 129 2-s2.0-0033856110 (Pubitemid 30609989)
37. Maehama T., Okahara F., Kanaho Y., The tumour suppressor PTEN: involvement of a tumour suppressor candidate protein in PTEN turnover. Biochemical Society Transactions 2004 32 2 343 347 2-s2.0-2342481786 10.1042/BST0320343 (Pubitemid 38582124)
38. Kim S. S., Yoo N. J., Jeong E. G., Kim M. S., Lee S. H., Expression of NEDD-1, a PTEN regulator, in gastric and colorectal carcinomas. APMIS 2008 116 9 779 784 2-s2.0-57349140689 10.1111/j.1600-0463.2008.00999.x
39. Wang X., Trotman L. C., Koppie T., Alimonti A., Chen Z., Gao Z., Wang J., Erdjument-Bromage H., Tempst P., Cordon-Cardo C., Pandolfi P. P., Jiang X., NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell 2007 128 1 129 139 2-s2.0-33845991111 10.1016/j.cell.2006.11.039 (Pubitemid 46048884)
40. Tsao H., Zhang X., Benoit E., Haluska F. G., Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. Oncogene 1998 16 26 3397 3402 2-s2.0-0032474749 (Pubitemid 28349682)
41. Yin Y., Shen W. H., PTEN: a new guardian of the genome. Oncogene 2008 27 41 5443 5453 2-s2.0-51849086880 10.1038/onc.2008.241
42. Parmiter A. H., Balaban G., Clark W. H., Nowell P. C., Possible involvement of the chromosome region 10q24→q26 in early stages of melanocytic neoplasia. Cancer Genetics and Cytogenetics 1988 30 2 313 317 2-s2.0-0023889925
43. Thompson F. H., Emerson J., Olson S., Weinstein R., Leavitt S. A., Leong S. P. L., Emerson S., Trent J. M., Nelson M. A., Salmon S. E., Taetle R., Cytogenetics of 158 patients with regional or disseminated melanoma: subset analysis of near-diploid and simple karyotypes. Cancer Genetics and Cytogenetics 1995 83 2 93 104 2-s2.0-0029148164 10.1016/0165-4608(95)00057-V
44. Mertens F., Johansson B., Höglund M., Mitelman F., Chromosomal imbalance maps of malignant solid tumors: a cytogenetic survey of 3185 neoplasms. Cancer Research 1997 57 13 2765 2780 2-s2.0-0030825508 (Pubitemid 27283792)
45. Bastian B. C., LeBoit P. E., Hamm H., Bröcker E. B., Pinkel D., Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Research 1998 58 10 2170 2175 2-s2.0-0032523833 (Pubitemid 28232904)
46. Cheung M., Sharma A., Madhunapantula S. V., Robertson G. P., Akt3 and mutant B-Raf cooperate to promote early melanoma development. Cancer Research 2008 68 9 3429 3439 2-s2.0-44849096481 10.1158/0008-5472.CAN-07-5867
47. Dankort D., Curley D. P., Cartlidge R. A., Nelson B., Karnezis A. N., Damsky W. E., You M. J., DePinho R. A., McMahon M., Bosenberg M., BrafV cooperates with Pten loss to induce metastatic melanoma. Nature Genetics 2009 41 5 544 552 2-s2.0-65649147543 10.1038/ng.356
48. Shao Y., Aplin A. E., Andrew.Aplin@KimmelCancerCenter.Org Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. Cancer Research 2010 70 16 6670 6681 10.1158/0008-5472.CAN-09-4471
49. Wang Y., DiGiovanna J. J., Stern J. B., Hornyak T. J., Raffeld M., Khan S. G., Oh K. S., Hollander M. C., Dennis P. A., Kraemer K. H., Evidence of ultraviolet type mutations in xeroderma pigmentosum melanomas. Proceedings of the National Academy of Sciences of the United States of America 2009 106 15 6279 6284 2-s2.0-65549163889 10.1073/pnas.0812401106
50. Costello J. F., Frühwald M. C., Smiraglia D. J., Rush L. J., Robertson G. P., Gao X., Wright F. A., Feramisco J. D., Peltomäki P., Lang J. C., Schuller D. E., Yu LI., Bloomfield C. D., Caligiuri M. A., Yates A., Nishikawa R., Su Huang H. J., Petrelli N. J., Zhang X., O'Dorisio M. S., Held W. A., Cavenee W. K., Plass C., Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nature Genetics 2000 24 2 132 138 2-s2.0-0343621494 10.1038/72785 (Pubitemid 30094712)
51. Furuta J., Umebayashi Y., Miyamoto K., Kikuchi K., Otsuka F., Sugimura T., Ushijima T., Promoter methylation profiling of 30 genes in human malignant melanoma. Cancer Science 2004 95 12 962 968 2-s2.0-11844302899 10.1111/j.1349-7006.2004.tb03184.x (Pubitemid 40089588)
52. Tsao H., Zhang X., Benoit E., Haluska F. G., Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. Oncogene 1998 16 26 3397 3402 2-s2.0-0032474749 (Pubitemid 28349682)
53. Guldberg P., Thor Straten P., Birck A., Ahrenkiel V., Kirkin A. F., Zeuthen J., Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Research 1997 57 17 3660 3663 2-s2.0-0030777104 (Pubitemid 27381203)
54. Böni R., Vortmeyer A. O., Burg G., Hofbauer G., Zhuang Z., The PTEN tumour suppressor gene and malignant melanoma. Melanoma Research 1998 8 4 300 302 2-s2.0-0031659223 10.1097/00008390-199808000-00002 (Pubitemid 28442560)
55. Celebi J. T., Shendrik I., Silvers D. N., Peacocke M., Identification of PTEN mutations in metastatic melanoma specimens. Journal of Medical Genetics 2000 37 9 653 657 2-s2.0-0033833298
56. Birck A., Ahrenkiel V., Zeuthen J., Hou-Jensen K., Guldberg P., Mutation and allelic loss of the PTEN/MMAC1 gene in primary and metastatic melanoma biopsies. Journal of Investigative Dermatology 2000 114 2 277 280 2-s2.0-0034086867 10.1046/j.1523-1747.2000.00877.x (Pubitemid 30417761)
57. Reifenberger J., Wolter M., Boström J., Büschges R., Schulte K. W., Megahed M., Ruzicka T., Reifenberger G., Allelic losses on chromosome arm 10q and mutation of the PTEN (MMAC1) tumour suppressor gene in primary and metastatic malignant melanomas. Virchows Archiv 2000 436 5 487 493 2-s2.0-0012746941 10.1007/s004280050477 (Pubitemid 30312165)
58. Poetsch M., Dittberner T., Woenckhaus C., PTEN/MMAC1 in malignant melanoma and its importance for tumor progression. Cancer Genetics and Cytogenetics 2001 125 1 21 26 2-s2.0-0035074472 10.1016/S0165-4608(00)00353-8 (Pubitemid 32288768)
59. Robertson G. P., Furnari F. B., Miele M. E., Glendening M. J., Welch D. R., Fountain J. W., Lugo T. G., Huang H. J. S., Cavenee W. K., In vitro loss of heterozygosity targets the PTEN/MMAC1 gene in melanoma. Proceedings of the National Academy of Sciences of the United States of America 1998 95 16 9418 9423 2-s2.0-0032483009 10.1073/pnas.95.16.9418 (Pubitemid 28506246)
60. Tsao H., Zhang X., Fowlkes K., Haluska F. G., Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Research 2000 60 7 1800 1804 2-s2.0-0034085811 (Pubitemid 30207633)
61. Bonazzi V. F., Irwin D., Hayward N. K., Identification of candidate tumor suppressor genes inactivated by promoter methylation in melanoma. Genes Chromosomes and Cancer 2009 48 1 10 21 2-s2.0-58049188918 10.1002/gcc.20615
62. Liu S., Ren S., Howell P., Fodstad O., Riker A. I., Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling. Pigment Cell and Melanoma Research 2008 21 5 545 558 2-s2.0-49649125674 10.1111/j.1755-148X.2008.00484.x
63. Zhou X. P., Gimm O., Hampel H., Niemann T., Walker M. J., Eng C., Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. American Journal of Pathology 2000 157 4 1123 1128 2-s2.0-0033819340
64. Pollock P. M., Trent J. M., The genetics of cutaneous melanoma. Clinics in Laboratory Medicine 2000 20 4 667 690 2-s2.0-0034486175 (Pubitemid 32146703)
65. Saida T., Recent advances in melanoma research. Journal of Dermatological Science 2001 26 1 1 13 2-s2.0-0035040353 10.1016/S0923-1811(01)00085-8 (Pubitemid 32372649)
66. Franke T. F., PI3K/Akt: getting it right matters. Oncogene 2008 27 50 6473 6488 2-s2.0-54949109808 10.1038/onc.2008.313
67. Aziz S. A., Davies M., Pick E., Zito C., Jilaveanu L., Camp R. L., Rimm D. L., Kluger Y., Kluger H. M., Phosphatidylinositol-3-kinase as a therapeutic target in melanoma. Clinical Cancer Research 2009 15 9 3029 3036 2-s2.0-65649126397 10.1158/1078-0432.CCR-08-2768
68. Marone R., Cmiljanovic V., Giese B., Wymann M. P., Targeting phosphoinositide 3-kinase-moving towards therapy. Biochimica et Biophysica Acta 2008 1784 1 159 185 2-s2.0-38149120449 10.1016/j.bbapap.2007.10.003
69. Blume-Jensen P., Hunter T., Oncogenic kinase signalling. Nature 2001 411 6835 355 365 2-s2.0-0035902180 10.1038/35077225 (Pubitemid 32467045)
70. Testa J. R., Bellacosa A., AKT plays a central role in tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America 2001 98 20 10983 10985 2-s2.0-0035949699 10.1073/pnas.211430998 (Pubitemid 32928669)
71. Nicholson K. M., Anderson N. G., The protein kinase B/Akt signalling pathway in human malignancy. Cellular Signalling 2002 14 5 381 395 2-s2.0-0036185848 10.1016/S0898-6568(01)00271-6 (Pubitemid 34214843)
72. Rodriguez-Viciana P., Warne P. H., Khwaja A., Marte B. M., Pappin D., Das P., Waterfield M. D., Ridley A., Downward J., Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 1997 89 3 457 467 2-s2.0-0030911052 10.1016/S0092-8674(00)80226-3 (Pubitemid 27220890)
73. Kauffmann-Zeh A., Rodriguez-Viciana P., Ulrich E., Gilbert C., Coffer P., Downward J., Evan G., Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature 1997 385 6616 544 548 2-s2.0-0031028730 10.1038/385544a0 (Pubitemid 27074674)
74. Polsky D., Cordon-Cardo C., Oncogenes in melanoma. Oncogene 2003 22 20 3087 3091 2-s2.0-0038795112 10.1038/sj.onc.1206449 (Pubitemid 36713760)
75. Shayesteh L., Lu Y., Kuo W. L., Baldocchi R., Godfrey T., Collins C., Pinkel D., Powell B., Mills G. B., Gray J. W., PlK3CA is implicated as an oncogene in ovarian cancer. Nature Genetics 1999 21 1 99 102 2-s2.0-0032590011 10.1038/5042 (Pubitemid 29036292)
76. Ma Y. Y., Wei S. J., Lin Y. C., PIK3CA as an oncogene in cervical cancer. Oncogene 2000 19 2739 2744
77. Tachiiri S., Sasai K., Oya N., Hiraoka M., Enhanced cell killing by overexpression of dominant-negative phosphatidylinositol 3-kinase subunit, Δp85, following genotoxic stresses. Japanese Journal of Cancer Research 2000 91 12 1314 1318 2-s2.0-0034520342 (Pubitemid 32042367)
78. Brazil D. P., Park J., Hemmings B. A., PKB binding proteins: getting in on the Akt. Cell 2002 111 3 293 303 2-s2.0-0036849331 10.1016/S0092-8674(02) 01083-8 (Pubitemid 35341386)
79. Scheid M. P., Woodgett J. R., PKB/AKT: functional insights from genetic models. Nature Reviews Molecular Cell Biology 2001 2 10 760 768 2-s2.0-0035489468 10.1038/35096067 (Pubitemid 33679838)
80. Scheid M. P., Woodgett J. R., Unravelling the activation mechanisms of protein kinase B/Akt. FEBS Letters 2003 546 1 108 112 2-s2.0-0037862006 10.1016/S0014-5793(03)00562-3 (Pubitemid 36782290)
81. Bellacosa A., Testa J. R., Moore R., Larue L., A portrait of AKT kinases: human cancer and animal models depict a family with strong individualities. Cancer Biology and Therapy 2004 3 3 268 275 2-s2.0-15244344356 (Pubitemid 41350878)
82. Brazil D. P., Yang Z. Z., Hemmings B. A., Advances in protein kinase B signalling: AKTion on multiple fronts. Trends in Biochemical Sciences 2004 29 5 233 242 2-s2.0-2342565881 10.1016/j.tibs.2004.03.006 (Pubitemid 38591317)
83. Brazil D. P., Hemmings B. A., Ten years of protein kinase B signalling: a hard Akt to follow. Trends in Biochemical Sciences 2001 26 11 657 664 2-s2.0-0035499454 10.1016/S0968-0004(01)01958-2 (Pubitemid 33042488)
84. Datta S. R., Brunet A., Greenberg M. E., Cellular survival: a play in three akts. Genes and Development 1999 13 22 2905 2927 2-s2.0-0032752063 10.1101/gad.13.22.2905
85. Lietzke S. E., Bose S., Cronin T., Klarlund J., Chawla A., Czech M. P., Lambright D. G., Structural basis of 3-phosphoinositide recognition by Pleckstrin homology domains. Molecular Cell 2000 6 2 385 394 2-s2.0-0033634785
86. Ferguson K. M., Kavran J. M., Sankaran V. G., Fournier E., Isakoff S. J., Skolnik E. Y., Lemmon M. A., Structural basis for discrimination of 3-phosphoinositides by pleckstrin homology domains. Molecular Cell 2000 6 2 373 384 2-s2.0-0033635275
87. Jones P. F., Jakubowicz T., Hemmings B. A., Molecular cloning of a second form of rac protein kinase. Cell Regulation 1991 2 12 1001 1009 2-s2.0-0026270993
88. Andjelkovic M., Jones P. F., Grossniklaus U., Cron P., Schier A. F., Dick M., Bilbe G., Hemmings B. A., Developmental regulation of expression and activity of multiple forms of the Drosophila RAC protein kinase. Journal of Biological Chemistry 1995 270 8 4066 4075 2-s2.0-0028947862 10.1074/jbc.270.8. 4066
89. Alessi D. R., Andjelkovic M., Caudwell B., Cron P., Morrice N., Cohen P., Hemmings B. A., Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO Journal 1996 15 23 6541 6551 2-s2.0-0029804116 (Pubitemid 26413787)
90. Konishi H., Kuroda S., Tanaka M., Matsuzaki H., Ono Y., Kameyama K., Haga T., Kikkawa U., Molecular cloning and characterization of a new member of the RAC protein kinase family: association of the pleckstrin homology domain of three types of RAC protein kinase with protein kinase C subspecies and βγ subunits of G proteins. Biochemical and Biophysical Research Communications 1995 216 2 526 534 2-s2.0-0028799420 10.1006/bbrc.1995.2654
91. Brodbeck D., Hill M. M., Hemmings B. A., Two splice variants of protein kinase B γ have different regulatory capacity depending on the presence or absence of the regulatory phosphorylation site serine 472 in the carboxyl-terminal hydrophobic domain. Journal of Biological Chemistry 2001 276 31 29550 29558 2-s2.0-0035800763 10.1074/jbc.M104633200
92. Liao Y., Hung M. C., Physiological regulation of Akt activity and stability. American Journal of Translational Research 2010 2 1 19 42 2-s2.0-77953408308
93. Gonzalez E., McGraw T. E., The Akt kinases: isoform specificity in metabolism and cancer. Cell Cycle 2009 8 16 2502 2508 2-s2.0-69249208791
94. Chen W. S., Xu P. Z., Gottlob K., Chen M. L., Sokol K., Shiyanova T., Roninson I., Weng W., Suzuki R., Tobe K., Kadowaki T., Hay N., Growth retardation and increased apoptosis in mice with homozygous disruption of the akt1 gene. Genes and Development 2001 15 17 2203 2208 2-s2.0-0035448879 10.1101/gad.913901 (Pubitemid 32843832)
95. Garofalo R. S., Orena S. J., Rafidi K., Torchia A. J., Stock J. L., Hildebrandt A. L., Coskran T., Black S. C., Brees D. J., Wicks J. R., McNeish J. D., Coleman K. G., Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB β Journal of Clinical Investigation 2003 112 2 197 208 2-s2.0-0043245147 10.1172/JCI200316885 (Pubitemid 38056356)
96. Tschopp O., Yang Z. Z., Brodbeck D., Dummler B. A., Hemmings-Mieszczak M., Watanabe T., Michaelis T., Frahm J., Hemmings B. A., Essential role of protein kinase B γ (PKB γ /Akt3) in postnatal brain developmental but not in glucose homeostasis. Development 2005 132 13 2943 2954 2-s2.0-23144449547 10.1242/dev.01864 (Pubitemid 41086730)
97. Gonzalez E., McGraw T. E., Insulin-modulated Akt subcellular localization determines Akt isoform-specific signaling. Proceedings of the National Academy of Sciences of the United States of America 2009 106 17 7004 7009 2-s2.0-66349098674 10.1073/pnas.0901933106
98. Dillon R. L., Marcotte R., Hennessy B. T., Woodgett J. R., Mills G. B., Muller W. J., Akt1 and Akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression. Cancer Research 2009 69 12 5057 5064 2-s2.0-67449136114 10.1158/0008-5472.CAN-08-4287
99. Brugge J., Hung M. C., Mills G. B., A new mutational aktivation in the PI3K pathway. Cancer Cell 2007 12 2 104 107 2-s2.0-34547574720 10.1016/j.ccr.2007.07.014 (Pubitemid 47199129)
100. Yang W. L., Wu C. Y., Wu J., Lin H. K., Regulation of Akt signaling activation by ubiquitination. Cell Cycle 2010 9 3 486 497 2-s2.0-77951917753
101. Hennessy B. T., Smith D. L., Ram P. T., Lu Y., Mills G. B., Exploiting the PI3K/AKT pathway for cancer drug discovery. Nature Reviews Drug Discovery 2005 4 12 988 1004 2-s2.0-32044466838 10.1038/nrd1902
102. Vanhaesebroeck B., Alessi D. R., The PI3K-PBK1 connection: more than just a road to PKB. Biochemical Journal 2000 346 3 561 576 2-s2.0-0034653608 10.1042/0264-6021:3460561 (Pubitemid 30171014)
103. Huang J., Manning B. D., A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochemical Society Transactions 2009 37 1 217 222 2-s2.0-59749091850 10.1042/BST0370217
104. Feldman M. E., Apsel B., Uotila A., Loewith R., Knight Z. A., Ruggero D., Shokat K. M., Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biology 2009 7 2, article e38 2-s2.0-65249156511 10.1371/journal.pbio.1000038
105. Andrabi S., Gjoerup O. V., Kean J. A., Roberts T. M., Schaffhausen B., Protein phosphatase 2A regulates life and death decisions via Akt in a context-dependent manner. Proceedings of the National Academy of Sciences of the United States of America 2007 104 48 19011 19016 2-s2.0-37649024728 10.1073/pnas.0706696104
106. Gao T., Furnari F., Newton A. C., PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Molecular Cell 2005 18 1 13 24 2-s2.0-15944406764 10.1016/j.molcel.2005.03.008 (Pubitemid 40444644)
107. Trotman L. C., Alimonti A., Scaglioni P. P., Koutcher J. A., Cordon-Cardo C., Pandolfi P. P., Identification of a tumour suppressor network opposing nuclear Akt function. Nature 2006 441 7092 523 527 2-s2.0-33745316089 10.1038/nature04809 (Pubitemid 44050155)
108. Ruvolo P. P., Ceramide regulates cellular homeostasis via diverse stress signaling pathways. Leukemia 2001 15 8 1153 1160 2-s2.0-0034882639 10.1038/sj.leu.2402197 (Pubitemid 32776437)
109. Yang W. L., Wang J., Chan C. H., Lee S. W., Campos A. D., Lamothe B., Hur L., Grabiner B. C., Lin X., Darnay B. G., Lin H. K., The E3 Ligase TRAF6 regulates akt ubiquitination and activation. Science 2009 325 5944 1134 1138 2-s2.0-69549116880 10.1126/science.1175065
110. Carpten J. D., Faber A. L., Horn C., Donoho G. P., Briggs S. L., Robbins C. M., Hostetter G., Boguslawski S., Moses T. Y., Savage S., Uhlik M., Lin A., Du J., Qian Y. W., Zeckner D. J., Tucker-Kellogg G., Touchman J., Patel K., Mousses S., Bittner M., Schevitz R., Lai M. H. T., Blanchard K. L., Thomas J. E., A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007 448 7152 439 444 2-s2.0-34547172596 10.1038/nature05933 (Pubitemid 47123510)
111. Davies M. A., Stemke-Hale K., Tellez C., Calderone T. L., Deng W., Prieto V. G., Lazar A. J. F., Gershenwald J. E., Mills G. B., A novel AKT3 mutation in melanoma tumours and cell lines. British Journal of Cancer 2008 99 8 1265 1268 2-s2.0-53849132331 10.1038/sj.bjc.6604637
112. Askham J. M., Platt F., Chambers P. A., Snowden H., Taylor C. F., Knowles M. A., AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K. Oncogene 2010 29 1 150 155 2-s2.0-73849134249 10.1038/onc.2009.315
113. Kim M. S., Jeong E. G., Yoo N. J., Lee S. H., Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias. British Journal of Cancer 2008 98 9 1533 1535 2-s2.0-43249115083 10.1038/sj.bjc.6604212 (Pubitemid 351652321)
114. Do H., hongD.do@petermac.org Solomon B., ben.solomon@petermac.org Mitchell P. L., paul.mitchell@austin.org.au Fox S. B., stephen.fox@petermac.org Dobrovic A., alex.dobrovic@petermac.org Detection of the transforming AKT1 mutation E17K in non-small cell lung cancer by high resolution melting. BMC Research Notes 2008 1, article 14 10.1186/1756-0500-1-14
115. Dhawan P., Singh A. B., Ellis D. L., Richmond A., Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor- κ B and tumor progression. Cancer Research 2002 62 24 7335 7342 2-s2.0-0037115394 (Pubitemid 36025257)
116. Woodgett J. R., Recent advances in the protein kinase B signaling pathway. Current Opinion in Cell Biology 2005 17 2 150 157 2-s2.0-15044363028 10.1016/j.ceb.2005.02.010 (Pubitemid 40380938)
117. Fresno Vara J. Á., Casado E., de Castro J., Cejas P., Belda-Iniesta C., González-Barón M., P13K/Akt signalling pathway and cancer. Cancer Treatment Reviews 2004 30 2 193 204 2-s2.0-1642617693 10.1016/j.ctrv.2003.07.007 (Pubitemid 38418057)
118. Kovacina K. S., Park G. Y., Bae S. S., Guzzetta A. W., Schaefer E., Birnbaum M. J., Roth R. A., Identification of a proline-rich Akt substrate as a 14-3-3 binding partner. Journal of Biological Chemistry 2003 278 12 10189 10194 2-s2.0-0037855834 10.1074/jbc.M210837200 (Pubitemid 36800278)
119. Wang L., Harris T. E., Roth R. A., Lawrence J. C. Jr., PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding. Journal of Biological Chemistry 2007 282 27 20036 20044 2-s2.0-34547099855 10.1074/jbc.M702376200 (Pubitemid 47100127)
120. Ikenoue T., Kanai F., Hikiba Y., Tanaka Y., Imamura J., Ohta M., Jazag A., Guleng B., Asaoka Y., Tateishi K., Kawakami T., Matsumura M., Kawabe T., Omata M., Functional consequences of mutations in a putative Akt phosphorylation motif of B-raf in human cancers. Molecular Carcinogenesis 2005 43 1 59 63 2-s2.0-20944448124 10.1002/mc.20102 (Pubitemid 40629203)
121. Packer L., Pavey S., Parker A., Stark M., Johansson P., Clarke B., Pollock P., Ringner M., Hayward N., Osteopontin is a downstream effector of the PI3-kinase pathway in melanomas that is inversely correlated with functional PTEN. Carcinogenesis 2006 27 9 1778 1786 2-s2.0-33747887710 10.1093/carcin/ bgl016 (Pubitemid 44288660)
122. Sharma A., Sharma A. K., Madhunapantula S. V., Desai D., Huh S. J., Mosca P., Amin S., Robertson G. P., Targeting Akt3 signaling in malignant melanoma using isoselenocyanates. Clinical Cancer Research 2009 15 5 1674 1685 2-s2.0-63449115826 10.1158/1078-0432.CCR-08-2214
123. Davies M. A., Stemke-Hale K., Lin E., Tellez C., Deng W., Gopal Y. N., Woodman S. E., Calderone T. C., Ju Z., Lazar A. J., Prieto V. G., Aldape K., Mills G. B., Gershenwald J. E., Integrated molecular and clinical analysis of AKT activation in metastatic melanoma. Clinical Cancer Research 2009 15 24 7538 7546 2-s2.0-73349128709 10.1158/1078-0432.CCR-09-1985
124. Laine J., Künstle G., Obata T., Sha MA., Noguchi M., The protooncogene TCL1 is an Akt kinase coactivator. Molecular Cell 2000 6 2 395 407 2-s2.0-0033636528
125. Laine J., Künstle G., Obata T., Noguchi M., Differential regulation of Akt kinase isoforms by the members of the TCL1 oncogene family. Journal of Biological Chemistry 2002 277 5 3743 3751 2-s2.0-0036479208 10.1074/jbc. M107069200 (Pubitemid 34953249)
126. Pekarsky Y., Koval A., Hallas C., Bichi R., Tresini M., Malstrom S., Russo G., Tsichlis P., Croce C. M., Tcl1 enhances Akt kinase activity and mediates its nuclear translocation. Proceedings of the National Academy of Sciences of the United States of America 2000 97 7 3028 3033 2-s2.0-0034724199 10.1073/pnas.040557697 (Pubitemid 30183249)
127. Walz H. A., Shi X., Chouinard MY., Bue C. A., Navaroli D. M., Hayakawa A., Zhou Q. L., Nadler J., Leonard D. M., Corvera S., Isoform-specific regulation of akt signaling by the endosomal protein WDFY2. Journal of Biological Chemistry 2010 285 19 14101 14108 2-s2.0-77951993812 10.1074/jbc.M110.110536
128. Schenck A., Goto-Silva L., Collinet C., Rhinn M., Giner A., Habermann B., Brand M., Zerial M., The endosomal protein Appl1 mediates Akt substrate specificity and cell survival in vertebrate development. Cell 2008 133 3 486 497 2-s2.0-42949092018 10.1016/j.cell.2008.02.044 (Pubitemid 351608689)
129. Shin S. S., Wall B. A., Goydos J. S., Chen S., AKT2 is a downstream target of metabotropic glutamate receptor 1 (Grm1). Pigment Cell and Melanoma Research 2010 23 1 103 111 2-s2.0-74349130963 10.1111/j.1755-148X.2009.00648.x
130. Staal S. P., Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America 1987 84 14 5034 5037 2-s2.0-0001582482 (Pubitemid 17095859)
131. Cheng J. Q., Godwin A. K., Bellacosa A., Taguchi T., Franke T. F., Hamilton T. C., Tsichlis P. N., Testa J. R., AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proceedings of the National Academy of Sciences of the United States of America 1992 89 19 9267 9271 2-s2.0-0026667730 10.1073/pnas.89.19.9267
132. Cheng J. Q., Ruggeri B., Klein W. M., Sonoda G., Altomare D. A., Watson D. K., Testa J. R., Amplification of AKT2 in human pancreatic cancer cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proceedings of the National Academy of Sciences of the United States of America 1996 93 8 3636 3641 2-s2.0-0001457668 10.1073/pnas.93.8.3636 (Pubitemid 26127592)
133. Lu Y., Li Z., Sun M., Multiple gene alterations involved in the processor of human gastric carcinogenesis. Chinese Medical Journal 1995 75 11 679 682
134. Bellacosa A., De Feo D., Godwin A. K., Bell D. W., Cheng J. Q., Altomare D. A., Wan M., Dubeau L., Scambia G., Masciullo V., Ferrandina G., Benedetti
135. Van Dekken H., vandekken@path.fgg.eur.nl Geelen E., Dinjens W. N. M., Wijnhoven B. P. L., Tilanus H. W., Tanke H. J., Rosenberg C., Comparative genomic hybridization of cancer of the gastroesophageal junction: deletion of 14Q31-32.1 discriminates between esophageal (Barrett's) and gastric cardia adenocarcinomas. Cancer Research 1999 59 3 748 752 (Pubitemid 29076077)
136. Bellacosa A., De Feo D., Godwin A. K., Bell D. W., Cheng J. Q., Altomare D. A., Wan M., Dubeau L., Scambia G., Masciullo V., Ferrandina G., Benedetti Panici P., Mancuso S., Neri G., Testa J. R., Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. International Journal of Cancer 1995 64 4 280 285 2-s2.0-0029127042 10.1002/ijc.2910640412
137. Cheng J. Q., Ruggeri B., Klein W. M., Sonoda G., Altomare D. A., Watson D. K., Testa J. R., Amplification of AKT2 in human pancreatic cancer cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proceedings of the National Academy of Sciences of the United States of America 1996 93 8 3636 3641 2-s2.0-0001457668 10.1073/pnas.93.8.3636 (Pubitemid 26127592)
138. Thompson F. H., Nelson M. A., Trent J. M., Guan X. Y., Liu Y., Yang J. M., Emerson J., Adair L., Wymer J., Balfour C., Massey K., Weinstein R., Alberts D. S., Taetle R., Amplification of 19q13.1-q13.2 sequences in ovarian cancer: G-band, FISH, and molecular studies. Cancer Genetics and Cytogenetics 1996 87 1 55 62 2-s2.0-17444437679 10.1016/0165-4608(95)00248-0 (Pubitemid 26113607)
139. Waldmann V., Wacker J., Deichmann M., Mutations of the activation-associated phosphorylation sites at codons 308 and 473 of protein kinase B are absent in human melanoma. Archives of Dermatological Research 2001 293 7 368 372 2-s2.0-0034880946 10.1007/s004030100236 (Pubitemid 32757480)
140. Waldmann V., Wacker J., Deichmann M., Absence of mutations in the pleckstrin homology (PH) domain of protein kinase B (PKB/Akt) in malignant melanoma. Melanoma Research 2002 12 1 45 50 2-s2.0-0036189577 10.1097/00008390-200202000-00007 (Pubitemid 34183688)
141. Andjelković M., Jakubowicz T., Cron P., Ming X. F., Han J. W., Hemmings B. A., Activation and phosphorylation of a pleckstrin homology domain containing protein kinase (RAC-PK/PKB) promoted by serum and protein phosphatase inhibitors. Proceedings of the National Academy of Sciences of the United States of America 1996 93 12 5699 5704 2-s2.0-0029942186 10.1073/pnas.93.12.5699 (Pubitemid 26190743)
142. Sato S., Fujita N., Tsuruo T., Modulation of Akt kinase activity by binding to Hsp90. Proceedings of the National Academy of Sciences of the United States of America 2000 97 20 10832 10837 2-s2.0-0034718540
143. Fujita N., Sato S., Ishida A., Tsuruo T., Involvement of Hsp90 in signaling and stability of 3-phosphoinositide-dependent kinase-1. Journal of Biological Chemistry 2002 277 12 10346 10353 2-s2.0-0037155901 10.1074/jbc.M106736200 (Pubitemid 34968152)
144. Lin R. J., Lin Y. C., Yu A. L., miR- 149 * induces apoptosis by inhibiting Akt1 and E2F1 in human cancer cells. Molecular Carcinogenesis 2010 49 719 727
145. Roccaro A. M., Sacco A., Thompson B., Leleu X., Azab A. K., Azab F., Runnels J., Jia X., Ngo H. T., Melhem M. R., Lin C. P., Ribatti D., Rollins B. J., Witzig T. E., Anderson K. C., Ghobrial I. M., MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood 2009 113 26 6669 6680 2-s2.0-69249225706 10.1182/blood-2009-01-198408
146. Jetzt A., Howe J. A., Horn M. T., Maxwell E., Yin Z., Johnson D., Kumar C. C., Adenoviral-Mediated Expression of a Kinase-Dead Mutant of Akt Induces Apoptosis Selectively in Tumor Cells and Suppresses Tumor Growth in Mice. Cancer Research 2003 63 20 6697 6706 2-s2.0-0142188728 (Pubitemid 37322949)
147. Govindarajan B., Sligh J. E., Vincent B. J., Li M., Canter J. A., Nickoloff B. J., Rodenburg R. J., Smeitink J. A., Oberley L., Zhang Y., Slingerland J., Arnold R. S., Lambeth J. D., Cohen C., Hilenski LU., Griendling K., Martínez-Diez M., Cuezva J. M., Arbiser J. L., Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. Journal of Clinical Investigation 2007 117 3 719 729 2-s2.0-33847417986 10.1172/JCI30102 (Pubitemid 46348530)
148. Bedogni B., Warneke J. A., Nickoloff B. J., Giaccia A. J., Powell M. B., Notch1 is an effector of Akt and hypoxia in melanoma development. Journal of Clinical Investigation 2008 118 11 3660 3670 2-s2.0-55849139852 10.1172/JCI36157
149. Tsai J., Lee J. T., Wang W., Zhang J., Cho H., Mamo S., Bremer R., Gillette S., Kong J., Haass N. K., Sproesser K., Li L., Smalley K. S. M., Fong D., Zhu Y. L., Marimuthu A., Nguyen H., Lam B., Liu J., Cheung I., Rice J., Suzuki Y., Luu C., Settachatgul C., Shellooe R., Cantwell J., Kim S. H., Schlessinger J., Zhang K. Y. J., West B. L., Powell B., Habets G., Zhang C., Ibrahim P. N., Hirth P., Artis D. R., Herlyn M., Bollag G., Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proceedings of the National Academy of Sciences of the United States of America 2008 105 8 3041 3046 2-s2.0-42949149240 10.1073/pnas.0711741105 (Pubitemid 351723664)
150. Jiang C. C., Wroblewski D., Yang F., Hersey P., Peter.Hersey@newcastle. edu.au Xu D. Z., Xu.Zhang@newcastle.edu.au Human melanoma cells under endoplasmic reticulum stress are more susceptible to apoptosis induced by the BH3 mimetic obatoclax. Neoplasia 2009 11 9 945 955 10.1593/neo.09692
151. Tran M. A., Gowda R., Sharma A., Park E. J., Adair J., Kester M., Smith N. B., Robertson G. P., Targeting B-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development. Cancer Research 2008 68 18 7638 7649 2-s2.0-54849373400 10.1158/0008-5472.CAN-07-6614
152. Dai D. L., Martinka M., Li G., Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. Journal of Clinical Oncology 2005 23 7 1473 1482 2-s2.0-14944352371 10.1200/JCO.2005.07.168
153. Jiang K., Sun J., Cheng J., Djeu J. Y., Wei S., Sebti S., Akt mediates Ras downregulation of RhoB, a suppressor of transformation, invasion, and metastasis. Molecular and Cellular Biology 2004 24 12 5565 5576 2-s2.0-2942628062 10.1128/MCB.24.12.5565-5576.2004 (Pubitemid 38738186)
154. Alessi D. R., Cuenda A., Cohen P., Dudley D. T., Saltiel A. R., PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. Journal of Biological Chemistry 1995 270 46 27489 27494 2-s2.0-0028884033 10.1074/jbc.270.46.27489
155. Obata T., Yaffe M. B., Leparc G. G., Piro E. T., Maegawa H., Kashiwagi A., Kikkawa R., Cantley L. C., Peptide and protein library screening defines optimal substrate motifs for AKT/PKB. Journal of Biological Chemistry 2000 275 46 36108 36115 2-s2.0-0034680838 10.1074/jbc.M005497200
156. Li G., Satyamoorthy K., Herlyn M., N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells. Cancer Research 2001 61 9 3819 3825 2-s2.0-0035328628 (Pubitemid 32694999)
157. Kang S. S., Kwon T., Kwon D. Y., Do S. I., Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit. Journal of Biological Chemistry 1999 274 19 13085 13090 2-s2.0-0033532056 10.1074/jbc.274.19.13085 (Pubitemid 29220430)
158. Kwon T., Kwon D. Y., Chun J., Kim J. H., Kang S. S., Akt protein kinase inhibits Rac1-GTP binding through phosphorylation at serine 71 of Rac1. Journal of Biological Chemistry 2000 275 1 423 428 2-s2.0-0034614606 10.1074/jbc.275.1.423 (Pubitemid 30039001)
159. Wajapeyee N., Serra R. W., Zhu X., Mahalingam M., Green M. R., Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 2008 132 3 363 374 2-s2.0-38849168162 10.1016/j.cell.2007. 12.032 (Pubitemid 351191995)
160. Houben R., Ortmann S., Drasche A., Troppmair J., Herold M. J., Becker J. C., Proliferation arrest in B-Raf mutant melanoma cell lines upon MAPK pathway activation. Journal of Investigative Dermatology 2009 129 2 406 414 2-s2.0-58549095049 10.1038/jid.2008.214
161. Zhao Y., Zhang Y., Yang Z., Li A., Dong J., Simultaneous knockdown of BRAF and expression of INK4A in melanoma cells leads to potent growth inhibition and apoptosis. Biochemical and Biophysical Research Communications 2008 370 3 509 513 2-s2.0-42749085117 10.1016/j.bbrc.2008.03.148
162. Goel V. K., Ibrahim N., Jiang G., Singhal M., Fee S., Flotte T., Westmoreland S., Haluska F. S., Hinds P. W., Haluska F. G., Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice. Oncogene 2009 28 23 2289 2298 2-s2.0-67349212438 10.1038/onc.2009.95
163. Saito A., Narasimhan P., Hayashi T., Okuno S., Ferrand-Drake M., Chan P. H., phchan@stanford.edu Neuroprotective role of a proline-rich akt substrate in apoptotic neuronal cell death after stroke: relationships with nerve growth factor. Journal of Neuroscience 2004 24 7 1584 1593 10.1523/JNEUROSCI.5209-03. 2004 (Pubitemid 38240953)
164. Huang B., Porter G., Expression of proline-rich Akt-substrate PRAS40 in cell survival pathway and carcinogenesis. Acta Pharmacologica Sinica 2005 26 10 1253 1258 2-s2.0-26044474979 10.1111/j.1745-7254.2005.00184.x (Pubitemid 41406643)
165. Oshiro N., Takahashi R., Yoshino K. I., Tanimura K., Nakashima A., Eguchi S., Miyamoto T., Hara K., Takehana K., Avruch J., Kikkawa U., Yonezawa K., The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1. Journal of Biological Chemistry 2007 282 28 20329 20339 2-s2.0-34547133519 10.1074/jbc.M702636200 (Pubitemid 47100038)
166. Sancak Y., Thoreen C. C., Peterson T. R., Lindquist R. A., Kang S. A., Spooner E., Carr S. A., Sabatini D. M., PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Molecular Cell 2007 25 6 903 915 2-s2.0-33947264077 10.1016/j.molcel.2007.03.003 (Pubitemid 46436534)
167. Nascimento E. B. M., Snel M., Guigas B., van der Zon G. C. M., Kriek J., Maassen J. A., Jazet I. M., Diamant M., Ouwens D. M., Phosphorylation of PRAS40 on Thr246 by PKB/AKT facilitates efficient phosphorylation of Ser183 by mTORC1. Cellular Signalling 2010 22 6 961 967 2-s2.0-77949912176 10.1016/j.cellsig.2010. 02.002
168. Patel S., Woodgett J., Glycogen synthase kinase-3 and cancer: good cop, bad cop? Cancer Cell 2008 14 5 351 353 2-s2.0-54549120290 10.1016/j.ccr.2008.10. 013
169. Luo J., Glycogen synthase kinase 3 β (GSK3 β) in tumorigenesis and cancer chemotherapy. Cancer Letters 2009 273 2 194 200 2-s2.0-57349143530 10.1016/j.canlet.2008.05.045
170. Bellei B., Flori E., Izzo E., Maresca V., Picardo M., GSK3 β inhibition promotes melanogenesis in mouse B16 melanoma cells and normal human melanocytes. Cellular Signalling 2008 20 10 1750 1761 2-s2.0-49549120607 10.1016/j.cellsig.2008.06.001
171. Ougolkov A. V., Billadeau D. D., Targeting GSK-3: a promising approach for cancer therapy? Future Oncology 2006 2 1 91 100 2-s2.0-33646795341 10.2217/14796694.2.1.91
172. Panka D. J., Cho D. C., Atkins M. B., Mier J. W., GSK-3 β inhibition enhances sorafenib-induced apoptosis in melanoma cell lines. Journal of Biological Chemistry 2008 283 2 726 732 2-s2.0-38149102519 10.1074/jbc. M705343200
173. Smalley K. S. M., Contractor R., Haass N. K., Kulp A. N., Atilla G. E., Williams D. S., Bregman H., Flaherty K. T., Soengas M. S., Meggers E., Herlyn M., An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. Cancer Research 2007 67 1 209 217 2-s2.0-33846440113 10.1158/0008-5472.CAN-06-1538 (Pubitemid 46142777)
174. Wilson W. 3rd, Baldwin A. S., Maintenance of constitutive I κ B kinase activity by glycogen synthase kinase-3 α / β in pancreatic cancer. Cancer Research 2008 68 19 8156 8163 2-s2.0-54249111455 10.1158/0008-5472.CAN-08-1061
175. Johnstone R. W., Ruefli A. A., Lowe S. W., Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002 108 2 153 164 2-s2.0-0037169358 10.1016/S0092-8674(02)00625-6 (Pubitemid 34161136)
176. Soengas M. S., Lowe S. W., Apoptosis and melanoma chemoresistance. Oncogene 2003 22 20 3138 3151 2-s2.0-0038793948 10.1038/sj.onc.1206454 (Pubitemid 36713766)
177. Poetsch M., Dittberner T., Woenckhaus C., PTEN/MMAC1 in malignant melanoma and its importance for tumor progression. Cancer Genetics and Cytogenetics 2001 125 1 21 26 2-s2.0-0035074472 10.1016/S0165-4608(00)00353-8 (Pubitemid 32288768)
178. Sharma A. K., Sharma A., Desai D., Madhunapantula S. V., Sung J. H., Robertson G. P., Amin S., Synthesis and anticancer activity comparison of phenylalkyl isoselenocyanates with corresponding naturally occurring and synthetic isothiocyanates. Journal of Medicinal Chemistry 2008 51 24 7820 7826 2-s2.0-58149090697 10.1021/jm800993r
179. Gaitonde S., De S. K., Tcherpakov M., Dewing A., Yuan H., Riel-Mehan M., Krajewski S., Robertson G., Pellecchia M., Ronai Z., BI-69A11-mediated inhibition of AKT leads to effective regression of xenograft melanoma. Pigment Cell and Melanoma Research 2009 22 2 187 195 2-s2.0-62149090949 10.1111/j.1755-148X.2009.00544.x
180. Rhodes N., Heerding D. A., Duckett D. R., Eberwein D. J., Knick V. B., Lansing T. J., McConnell R. T., Gilmer T. M., Zhang S. Y., Robell K., Kahana J. A., Geske R. S., Kleymenova E. V., Choudhry A. E., Lai Z., Leber J. D., Minthorn E. A., Strum S. L., Wood E. R., Huang P. S., Copeland R. A., Kumar R., Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Research 2008 68 7 2366 2374 2-s2.0-42049115641 10.1158/0008-5472.CAN-07-5783 (Pubitemid 351521811)
181. Kapetanovic I. M., Muzzio M., Hu S. C., Crowell J. A., Rajewski R. A., Haslam J. L., Jong L., Mccormick D. L., Pharmacokinetics and enhanced bioavailability of candidate cancer preventative agent, SR13668 in dogs and monkeys. Cancer Chemotherapy and Pharmacology 2010 65 6 1109 1116 2-s2.0-77951922835 10.1007/s00280-009-1116-4
182. Chao W. R., Yean D., Amin K., Green C., Jong L., Computer-aided rational drug design: a novel agent (SR13668) designed to mimic the unique anticancer mechanisms of dietary indole-3-carbinol to block Akt signaling. Journal of Medicinal Chemistry 2007 50 15 3412 3415 2-s2.0-34547590883 10.1021/jm070040e (Pubitemid 47195447)
183. Ernst D. S., Eisenhauer E., Wainman N., Davis M., Lohmann R., Baetz T., Belanger K., Smylie M., Phase II study of perifosine in previously untreated patients with metastatic melanoma. Investigational New Drugs 2005 23 6 569 575 2-s2.0-31544448600 10.1007/s10637-005-1157-4 (Pubitemid 43162477)
184. Paraiso K. H. T., Fedorenko I. V., Cantini L. P., Munko A. C., Hall M., Sondak V. K., Messina J. L., Flaherty K. T., Smalley K. S. M., Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. British Journal of Cancer 2010 102 12 1724 1730 2-s2.0-77953276524 10.1038/sj.bjc.6605714
185. Smalley K. S. M., Flaherty K. T., Integrating BRAF/MEK inhibitors into combination therapy for melanoma. British Journal of Cancer 2009 100 3 431 435 2-s2.0-59649123810 10.1038/sj.bjc.6604891
186. Krasilnikov M., Ivanov V. N., Dong J., Ronai Z., ERK and PI3K negatively regulate STAT-transcriptional activities in human melanoma cells: implications towards sensitization to apoptosis. Oncogene 2003 22 26 4092 4101 2-s2.0-0038001179 10.1038/sj.onc.1206598 (Pubitemid 36819649)
187. Meier F., Schittek B., Busch S., Garbe C., Smalley K., Satyamoorthy K., Li G., Herlyn M., The Ras/Raf/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Frontiers in Bioscience 2005 10 3 2986 3001 2-s2.0-21344456180 (Pubitemid 40910537)
188. Tran M. A., Smith C. D., Kester M., Robertson G. P., Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development. Clinical Cancer Research 2008 14 11 3571 3581 2-s2.0-47949086963 10.1158/1078-0432.CCR-07-4881
189. Lasithiotakis K. G., Sinnberg T. W., Schittek B., Flaherty K. T., Kulms D., MacZey E., Garbe C., Meier F. E., Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. Journal of Investigative Dermatology 2008 128 8 2013 2023 2-s2.0-47349099502 10.1038/jid.2008.44 (Pubitemid 352001225)
190. LoPiccolo J., Blumenthal G. M., Bernstein W. B., Dennis P. A., Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resistance Updates 2008 11 1-2 32 50 2-s2.0-43049131769 10.1016/j.drup.2007.11.003
191. Bedogni B., Welford S. M., Kwan A. C., Ranger-Moore J., Saboda K., Powell M. B., Inhibition of phosphatidylinositol-3-kinase and mitogen-activated protein kinase kinase 1/2 prevents melanoma development and promotes melanoma regression in the transgenic TPRas mouse model. Molecular Cancer Therapeutics 2006 5 12 3071 3077 2-s2.0-33846230965 10.1158/1535-7163.MCT-06-0269 (Pubitemid 46092048)
192. Yang J., Splittgerber R., Yull F. E., Kantrow S., Ayers G. D., Karin M., Richmond A., ann.richmond@vanderbilt.edu Conditional ablation of Ikkb inhibits melanoma tumor development in mice. Journal of Clinical Investigation 2010 120 7 2563 2574 10.1172/JCI42358
193. Yao J.-E., yaojine@yahoo.com.cn Yan M., yanmin@mail.sysucc.org.cn Guan Z., drguanzhong@yahoo.com.cn Pan C.-B., docpcb@126.com Xia L.-P., xialiangping@163.com Li C.-X., lichuanh@mail.syS.edu.cn Wang L.-H., wanglihui100@163.com Long Z.-J., biolongzijie@yahoo.com.cn Zhao Y., zhaoyanzs@126.com Li M.-W., limingwei2000@163.com Zheng F.-M., mongolia8206@yahoo.com.cn Xu J., xujiercl@yahoo.com.cn Lin D.-J., liuqlab@yahoo.com Liu Q., liuq9@mail.syS.edu.cn Aurora-A down-regulates IkappaB α via Akt activation and interacts with insulin-like growth factor-1 induced phosphatidylinositol 3-kinase pathway for cancer cell survival. Molecular Cancer 2009 8, article 95 10.1186/1476-4598-8-95
194. Dey A., Wong E., Kua N., Hsiang L. T., Tergaonkar V., Lane D., Hexamethylene bisacetamide (HMBA) simultaneously targets AKT and MAPK pathway and represses NF κ B activity: implications for cancer therapy. Cell Cycle 2008 7 23 3759 3767 2-s2.0-57349169255
195. Madhunapantula S. V., Desai D., Sharma A., Sung J. H., Amin S., Robertson G. P., PBISe, a novel selenium-containing drug for the treatment of malignant melanoma. Molecular Cancer Therapeutics 2008 7 5 1297 1308 2-s2.0-49849086366 10.1158/1535-7163.MCT-07-2267
196. Michaloglou C., Vredeveld L. C. W., Mooi W. J., Peeper D. S., BRAF in benign and malignant human tumours. Oncogene 2008 27 7 877 895 2-s2.0-38949131824 10.1038/sj.onc.1210704 (Pubitemid 351225383)
197. Michaloglou C., Vredeveld L. C. W., Soengas M. S., Denoyelle C., Kuilman T., Van Der Horst C. M. A. M., Majoor D. M., Shay J. W., Mooi W. J., Peeper D. S., BRAF-associated senescence-like cell cycle arrest of human naevi. Nature 2005 436 7051 720 724 2-s2.0-23244447037 10.1038/nature03890 (Pubitemid 41117276)
198. Engelman J. A., Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nature Reviews Cancer 2009 9 8 550 562 2-s2.0-67749122122 10.1038/nrc2664